Published in AAPS J on August 02, 2013
New Financial and Research Models for Pediatric Orphan Drug Development - Focus on the NCATS TRND Program. Pharmaceut Med (2014) 0.75
The Effectiveness and Safety of Topical Capsaicin in Postherpetic Neuralgia: A Systematic Review and Meta-analysis. Front Pharmacol (2017) 0.75
The Need for Pediatric Formulations to Treat Children with HIV. AIDS Res Treat (2016) 0.75
Moving toward a paradigm shift in the regulatory requirements for pediatric medicines. Eur J Pediatr (2016) 0.75
Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res (2005) 4.13
Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther (2012) 2.39
Developing a new formulation of sodium phenylbutyrate. Arch Dis Child (2012) 1.77
Liquid medication dosing errors. J Fam Pract (2000) 1.67
The economics of pediatric formulation development for off-patent drugs. Clin Ther (2008) 1.61
Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J (2005) 1.53
Performance qualification of an electronic tongue based on ICH guideline Q2. J Pharm Biomed Anal (2009) 1.36
Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth (2011) 1.31
A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther (2010) 1.30
Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res (2003) 1.28
Dosing in children. Clin Pharmacol Ther (2010) 1.16
Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm (2012) 1.16
Delivery devices for the administration of paediatric formulations: overview of current practice, challenges and recent developments. Int J Pharm (2011) 1.15
The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol (2009) 1.12
Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv (2011) 1.12
Evaluation of a taste sensor instrument (electronic tongue) for use in formulation development. Int J Pharm (2008) 1.11
Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet (2012) 1.10
Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med (2009) 1.09
Pharmaceutical equivalence by design for generic drugs: modified-release products. Pharm Res (2011) 0.99
Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol (2011) 0.99
Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int J Pharm (2011) 0.99
Prescribing for children - taste and palatability affect adherence to antibiotics: a review. Arch Dis Child (2011) 0.96
Pediatric drugs--a review of commercially available oral formulations. J Pharm Sci (2008) 0.95
Paediatric and geriatric drug delivery. Expert Opin Drug Deliv (2007) 0.95
Orally disintegrating mini-tablets (ODMTs)--a novel solid oral dosage form for paediatric use. Eur J Pharm Biopharm (2011) 0.92
Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study. Arch Dis Child (2012) 0.91
The manipulation of drugs to obtain the required dose: systematic review. J Adv Nurs (2012) 0.86
If children ruled the pharmaceutical industry: the need for pediatric formulations. Drug News Perspect (2010) 0.86
Electronic tongue for pharmaceutical analytics: quantification of tastes and masking effects. Anal Bioanal Chem (2004) 0.84
A modern view of excipient effects on bioequivalence: case study of sorbitol. Pharm Res (2006) 0.83
Tablet splitting: Product quality assessment of metoprolol succinate extended release tablets. Int J Pharm (2010) 0.82
Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children. Br J Clin Pharmacol (2012) 0.82
Adherence issues related to the selection of antistaphylococcal or antifungal antibiotic suspensions for children. Clin Pediatr (Phila) (2006) 0.80
Novel milk-based oral formulations: proof of concept. Int J Pharm (2010) 0.79
Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS. Pharm Res (2012) 0.78
Study of microbial contamination and dosing accuracy of oral dispensers. J Clin Pharm Ther (2010) 0.77
Selecting a systemic corticosteroid for acute asthma in young children. J Pediatr (2003) 0.77
Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol (2008) 2.46
Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J (2005) 1.53
Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery. J Pediatr (2011) 1.47
A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm (2006) 1.43
Taste sensing systems (electronic tongues) for pharmaceutical applications. Int J Pharm (2010) 1.39
Laparoscopy at all costs? Not now during COVID-19 outbreak and not for acute care surgery and emergency colorectal surgery: A practical algorithm from a hub tertiary teaching hospital in Northern Lombardy, Italy. J Trauma Acute Care Surg (2020) 1.39
Monte Carlo simulations for the study of drug release from matrices with high and low diffusivity areas. Int J Pharm (2007) 1.38
Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol (2008) 1.33
On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm (2005) 1.31
Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res (2003) 1.28
Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol (2008) 1.24
A comparative study on two electronic tongues for pharmaceutical formulation development. J Pharm Biomed Anal (2011) 1.23
Fractional kinetics in drug absorption and disposition processes. J Pharmacokinet Pharmacodyn (2009) 1.20
Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J (2009) 1.20
Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group. Pediatr Blood Cancer (2010) 1.14
Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J (2011) 1.14
A commentary on fractionalization of multi-compartmental models. J Pharmacokinet Pharmacodyn (2010) 1.13
The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol (2009) 1.12
Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv (2011) 1.12
Evaluation of a taste sensor instrument (electronic tongue) for use in formulation development. Int J Pharm (2008) 1.11
Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf (2009) 1.10
Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics (2013) 1.10
Challenges of developing palatable oral paediatric formulations. Int J Pharm (2008) 1.09
Withdrawal of generic budeprion for nonbioequivalence. N Engl J Med (2012) 1.09
An insight into the properties of a two-stage design in bioequivalence studies. Pharm Res (2013) 1.06
Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr (2008) 1.04
Modeling and simulation of adherence: approaches and applications in therapeutics. AAPS J (2005) 1.02
Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS (2015) 1.00
A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One (2011) 1.00
Novel analytical methods for the characterization of oral wafers. Eur J Pharm Biopharm (2009) 0.99
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol (2008) 0.99
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood (2013) 0.99
Population pharmacokinetic investigation of actinomycin-D in children and young adults. J Clin Pharmacol (2008) 0.98
Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. J Pediatr Pharmacol Ther (2011) 0.98
A time to keep and a time to cast away categories of tumor response. J Clin Oncol (2011) 0.97
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost (2002) 0.96
Comparative investigations on different polymers for the preparation of fast-dissolving oral films. J Pharm Pharmacol (2010) 0.95
Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. Anesth Analg (2010) 0.94
Fractional kinetics in multi-compartmental systems. J Pharmacokinet Pharmacodyn (2010) 0.94
Favorable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and preschool children. J Pediatr (2013) 0.94
Laparoscopic versus open appendectomy: a comparison of primary outcome measures. Saudi J Gastroenterol (2011) 0.93
Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. AAPS J (2012) 0.93
Analysis of dissolution data using modified versions of Noyes-Whitney equation and the Weibull function. Pharm Res (2006) 0.92
Development of oral taste masked diclofenac formulations using a taste sensing system. Int J Pharm (2012) 0.91
Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res (2013) 0.90
A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections. Ther Drug Monit (2009) 0.90
Utility of concentration-effect modeling and simulation in a thorough QT study of losmapimod. J Clin Pharmacol (2015) 0.90
Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf (2012) 0.89
In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. Eur J Pharm Sci (2002) 0.88
Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol (2013) 0.88
Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharm Res (2009) 0.88
Drug utilization in the pediatric intensive care unit: monitoring prescribing trends and establishing prioritization of pharmacotherapeutic evaluation of critically ill children. J Clin Pharmacol (2005) 0.88
Robotics in surgery. J Am Coll Surg (2003) 0.88
Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit (2011) 0.88
A sensitive and selective liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. J Mass Spectrom (2007) 0.87
Identification of biowaivers among Class II drugs: theoretical justification and practical examples. Pharm Res (2004) 0.87
Rational development of taste masked oral liquids guided by an electronic tongue. Int J Pharm (2010) 0.86
Bioequivalence of highly variable drugs: a comparison of the newly proposed regulatory approaches by FDA and EMA. Pharm Res (2011) 0.86
Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts. AAPS J (2007) 0.86
Novel delivery device for monolithical solid oral dosage forms for personalized medicine. Int J Pharm (2010) 0.85
Nonlinear dynamics in clinical pharmacology: the paradigm of cortisol secretion and suppression. Br J Clin Pharmacol (2002) 0.85
Oral drug delivery in personalized medicine: unmet needs and novel approaches. Int J Pharm (2010) 0.85
A reappraisal of drug release laws using Monte Carlo simulations: the prevalence of the Weibull function. Pharm Res (2003) 0.85
Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants. AAPS J (2013) 0.84
An informatics approach to assess pediatric pharmacotherapy: design and implementation of a hospital drug utilization system. J Clin Pharmacol (2007) 0.84
Engineering of pharmaceutical materials: an industrial perspective. J Pharm Sci (2008) 0.84
Quantitative assessment of the switchability of generic products. Eur J Pharm Sci (2013) 0.84
Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations. CNS Drugs (2014) 0.83
Surgical skill is predicted by the ability to detect errors. Am J Surg (2005) 0.83
Oromucosal film preparations: classification and characterization methods. Expert Opin Drug Deliv (2013) 0.83
Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol (2003) 0.83
The mean dissolution time depends on the dose/solubility ratio. Pharm Res (2003) 0.83
Tablet splitting: Product quality assessment of metoprolol succinate extended release tablets. Int J Pharm (2010) 0.82
Pharmacokinetics and pharmacodynamics in the critically ill child. Pediatr Clin North Am (2008) 0.82
Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis (2002) 0.82
A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research. J Pharm Biomed Anal (2008) 0.82
Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies. J Clin Pharmacol (2013) 0.82
Quantitative structure-pharmacokinetic relationships for disposition parameters of cephalosporins. Eur J Pharm Sci (2003) 0.82
Separation and characterization of silybin, isosilybin, silydianin and silychristin in milk thistle extract by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr A (2006) 0.82
Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer. Ther Drug Monit (2010) 0.82
Novel scaled average bioequivalence limits based on GMR and variability considerations. Pharm Res (2004) 0.82
Assessment of test methods evaluating mucoadhesive polymers and dosage forms: an overview. Eur J Pharm Biopharm (2013) 0.82
Predictors of arterial blood pressure control during deliberate hypotension with sodium nitroprusside in children. Anesth Analg (2014) 0.82
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240. J Clin Pharmacol (2004) 0.82
Novel methods to assess bioequivalence. Expert Opin Drug Metab Toxicol (2010) 0.82
The surgical error examination is a novel method for objective technical knowledge assessment. Am J Surg (2003) 0.81
Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.81
Current regulatory approaches of bioequivalence testing. Expert Opin Drug Metab Toxicol (2012) 0.81
A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. Cancer Chemother Pharmacol (2005) 0.81
Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. Drug Metab Pharmacokinet (2013) 0.81
Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis. Int J Clin Pharmacol Ther (2013) 0.81
A model for transport and dispersion in the circulatory system based on the vascular fractal tree. Ann Biomed Eng (2003) 0.81
Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction. Anesth Analg (2006) 0.81
The reliability of multiple objective measures of surgery and the role of human performance. Am J Surg (2005) 0.81
Multivariate statistics of disposition pharmacokinetic parameters for structurally unrelated drugs used in therapeutics. Pharm Res (2002) 0.81